Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the rationale for exploring tasquinimod, an investigational agent targeting alarmin-driven inflammation, in patients with myelofibrosis. Dr Masarova explains that in preclinical studies, tasquinimod inhibited alarmin-driven inflammation and fibrosis, with evidence suggesting the agent may reverse fibrosis. She outlines the ongoing Phase I/II study (NCT06327100) evaluating tasquinimod as monotherapy after JAK inhibitor failure or in patients ineligible for JAK inhibitors, as well as in combination with the JAK inhibitors ruxolitinib or momelotinib. This interview took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, D.C.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.